LEXEO secures US FDA IND approval for LX2020 to treat PKP2-ACM
US-based gene therapy company LEXEO Therapeutics has received the US Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application for LX2020. LEXEO is engaged